Search peptides, terms, sources/
Research source · 2022

Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstrom syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period

About this source

Kind
Research
Design
Human clinical trial, RCT
Population
38 people with Bardet-Biedl or Alstrom syndrome, 19 per arm
Sample size
38
Primary or secondary
primary
Peer review
peer reviewed
Retraction status
None known
Date checked
14 November 2026

Limitations

Small trial in rare conditions. The abstract record read gives the result for people aged 12 and over with Bardet-Biedl syndrome but not the comparator rate.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.